A Study of ION251 Administered to Patients With Relapsed/Refractory Multiple Myeloma
Status:
Recruiting
Trial end date:
2024-01-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine the maximum-tolerated dose (MTD) and recommended
Phase 2 dose (RP2D) of ION251 in patients with relapsed/refractory multiple myeloma.